Supernus Pharmaceuticals, Inc.
SUPN
$48.27
$1.122.38%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 32.40% | 38.63% | 21.48% | 9.34% | -1.71% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 32.40% | 38.63% | 21.48% | 9.34% | -1.71% |
| Cost of Revenue | 62.12% | 47.17% | -7.14% | 3.67% | 117.36% |
| Gross Profit | 23.25% | 35.23% | 34.61% | 11.39% | -15.89% |
| SG&A Expenses | 43.88% | 34.27% | 52.48% | 36.58% | 10.07% |
| Depreciation & Amortization | 21.68% | 29.61% | 34.43% | 24.82% | 3.54% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 45.49% | 37.19% | 29.24% | 24.61% | 2.80% |
| Operating Income | -148.86% | -6.36% | -39.81% | -70.08% | -38.83% |
| Income Before Tax | -445.84% | -2.04% | -107.25% | -228.95% | -36.62% |
| Income Tax Expenses | 112.40% | -160.99% | -80.18% | -299.15% | -191.29% |
| Earnings from Continuing Operations | -359.44% | 80.61% | -126.78% | -217.20% | 12.97% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -359.44% | 80.61% | -126.78% | -217.20% | 12.97% |
| EBIT | -148.86% | -6.36% | -39.81% | -70.08% | -38.83% |
| EBITDA | -37.53% | 39.62% | -4.21% | -31.28% | -16.52% |
| EPS Basic | -350.30% | 81.20% | -125.90% | -214.30% | 10.88% |
| Normalized Basic EPS | -131.58% | -90.28% | -43.89% | -67.67% | -29.94% |
| EPS Diluted | -352.50% | 81.11% | -126.71% | -215.94% | 11.11% |
| Normalized Diluted EPS | -131.93% | -90.28% | -42.87% | -67.16% | -29.77% |
| Average Basic Shares Outstanding | 3.65% | 3.19% | 3.39% | 2.54% | 1.90% |
| Average Diluted Shares Outstanding | 2.52% | 3.19% | 1.56% | 0.96% | 1.65% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |